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Abstract
Background: Nonsense mutations in the X-linked methyl CpG-binding protein 2 (MECP2) comprise a significant proportion
of causative MECP2 mutations in Rett syndrome (RTT). Naturally occurring aminoglycosides, such as gentamicin, have been
shown to enable partial suppression of nonsense mutations related to several human genetic disorders, however, their
clinical applicability has been compromised by parallel findings of severe toxic effects. Recently developed synthetic NB
aminoglycosides have demonstrated significantly improved effects compared to gentamicin evident in substantially higher
suppression and reduced acute toxicity in vitro.
Results: We performed comparative study of suppression effects of the novel NB54 and gentamicin on three MECP2
nonsense mutations (R294X, R270X and R168X) common in RTT, using ex vivo treatment of primary fibroblasts from RTT
patients harboring these mutations and testing for the C-terminal containing full-length MeCP2. We observed that NB54
induces dose-dependent suppression of MECP2 nonsense mutations more efficiently than gentamicin, which was evident at
concentrations as low as 50 mg/ml. NB54 read-through activity was mutation specific, with maximal full-length MeCP2
recovery in R168X (38%), R270X (27%) and R294X (18%). In addition, the recovered MeCP2 was translocated to the cell
nucleus and moreover led to parallel increase in one of the most important MeCP2 downstream effectors, the brain derived
neurotrophic factor (BDNF).
Conclusion: Our findings suggest that NB54 may induce restoration of the potentially functional MeCP2 in primary RTT
fibroblasts and encourage further studies of NB54 and other rationally designed aminoglycoside derivatives as potential
therapeutic agents for nonsense MECP2 mutations in RTT.
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Introduction
Rett syndrome (RTT, MIM 312750) is a postnatal neurodevel-
opmental disorder predominantly occurring in girls with a
worldwide incidence of 1/10,000–15,000 female births [1].
Classical RTT patients suffer from profound cognitive and motor
disabilities usually apparent after the first year of life. In addition,
the majority of RTT patients also develop seizure disorder, and
various autonomic dysfunctions including breathing abnormalities,
sleep disorder and orthopedic complications. Loss of purposeful
hand use and emergence of stereotypic hand movements are the
hallmark of RTT. The major causative factor of RTT is deficiency
of the methyl CpG binding protein MECP2 at Xq28 [2], in which
over 200 mutations have been identified so far in classical and
atypical RTT patients [3]. The majority of RTT causative
mutations involve C.T transitions at the CpG hot-spots leading
to missense, nonsense and frame-shift mutations [4], mostly
originating de novo in the paternal germline [5]. Phenotypic
heterogeneity in RTT has been related, for the most part, to
MECP2 mutation type and localization, as well as X chromosome
inactivation (XCI) pattern [6]. However, not only MeCP2
deficiency but also its overdose is equally detrimental for the
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reminiscent of RTT [7,8].
The MECP2 gene encodes two isoform proteins, MeCP2_e1
and _e2 products of an alternative initiation at exon 1 and splicing
of exon 2 [9,10], both of which are nuclear and co-localize with
the methylated heterochromatin [11]. Previous studies suggested
that MeCP2 is a classical transcriptional repressor binding to
methylated promoters and recruiting the HDAC machinery to
induce chromatin condensation [12,13]. In neurons, MeCP2 has
been implicated in modulation of specific neuronal target genes in
activity dependent manner, specifically the brain derived neuro-
trophic factor (BDNF) [14,15]. However, more recent studies
proved that MeCP2 role in neurons is more flexible and complex,
as MeCP2 has been implicated in both repression and activation
of a large number of genes [16], in modulation of RNA splicing
[17], and most recently has been suggested to affect global
chromatin structure impacting on the entire neuronal genome
[18]. An important realization learned from RTT mouse models
was that MeCP2 dysfunction in mature neurons accounts for RTT
symptoms [19,20] and that postnatal restoration of MeCP2
deficiency in the CNS, even after RTT onset, can lead to the
reversal of neurological symptoms [21,22]. These findings have
lead to the notion that RTT rescue may be achieved by
pharmacological treatment that may induce MeCP2 up-regulation
in MeCP2 deficient neurons, nonetheless considering the impor-
tance of correct MeCP2 dosage [23].
Significant proportion (up to 60%) of the classical RTT is
caused by MECP2 nonsense mutations [24], leading to premature
translational termination and truncated protein products. Amino-
glycoside antibiotics, such as gentamicin, can induce suppression
of nonsense codons in mammalian cells by enabling partial read-
through and expression of functional proteins [25,26,27]. Partial
suppression effect of gentamicin was demonstrated in vitro and in
vivo for specific nonsense mutations related to human genetic
disorders [28,29,30]. Previous study using recombinant MeCP2
constructs harboring the most common RTT nonsense mutations,
R168X, R255X, R270X and R294X, showed that gentamicin can
recover MeCP2 read-through efficiency up to 10–22% depending
on the nucleotide context of a nonsense mutation [31]. In
addition, the recovered MeCP2 protein was traced to the cell
nucleus suggesting that gentamicin does not interfere with its
nuclear localization. However, clinical applicability of gentamicin
has been compromised by parallel findings of significant toxicity
associated with its long-term administration and with reduced
suppression efficiency at subtoxic doses [30], in addition to its
limited permeability through the blood-brain-barrier [32]. Syn-
thetic aminoglycosides, NB aminoglycosides, developed by
systematic structure-activity-toxicity design optimized for maximal
suppression effect and minimal toxicity [33], could be potential
candidates for nonsense suppression therapy in RTT. Experience
with the NB30 derivative suggested that it can induce significant
read-through of the p.R31X nonsense mutation related to Usher’s
syndrome with better biocompatibility and significantly reduced
toxicity compared to gentamicin and paromomycin [34]. The
newer NB54 compound demonstrated even lesser acute toxicity
and significantly higher suppression potency [35].
We presently report on experiments with NB54 and gentamicin
treating primary fibroblasts cultures derived from female RTT
patients harboring common MECP2 nonsense mutations, R294X,
R270X or R168X. We considered that non-transformed fibro-
blasts may provide a better experimental system for comparative
studies ex vivo of NB54 and gentamicin effects, avoiding limitations
of the transformed or transfected cell lines or unavailability of
complex tissues such as brain. We presently show that NB54 has
better read-through efficiency than gentamicin for MeCP2
harboring RTT causative nonsense mutations, as determined by
recovery of the C-terminal containing MeCP2 protein. In
addition, we show that NB54 treatment restores potentially
functional MeCP2, which is evident from its appropriate nuclear
localization and increased levels of BDNF.
Results
Efficiency of NB54 treatment compared to gentamicin
We performed experiments in primary RTT fibroblasts
harboring R168X, R270X or R294X mutations, treating them
in parallel with NB54 or gentamicin at concentrations ranging
from 50 to 800 mg/ml for duration of 5 days. Expression levels of
the full-length MeCP2 (approximately 75 kD) was evaluated using
MeCP2 C-terminal antibody and emerin as nuclear protein
reference; MeCP2 read-through efficiency was evaluated relative
to the human foreskin fibroblasts (HFF) expressing the normal
MeCP2. Figure 1 shows NB54 and gentamicin effects on R294X
(Fig. 1A), R270X (Fig. 1B) R168X (Fig. 1C) RTT fibroblasts,
relating to the full-length MeCP2 expression levels and MeCP2
read-through efficiency. Read-through efficiency was calculated
considering full length MeCP2 readings at each point normalized
to emerin for protein load correction, subtracting the no-drug
point in each experiment for correction of MeCP2 background
expression and XCI variability, and dividing by HFF reference for
fully active wild type MeCP2. In all RTT fibroblasts, NB54
treatment was more effective than gentamicin, enabling to achieve
higher read-though efficiency and higher MeCP2 expression
levels. Maximal MeCP2 read-though of 38% was detected in
R168X treated with 100 mg/ml NB54, compared to 18% - with
gentamicin at the same concentration (Fig. 1C). NB54 effect in
R270X and R168X fibroblasts was similar, with maximal MeCP2
read-through of 27% and 38% at 100 mg/ml, respectively, and
decreased efficiency in higher drug concentrations (Fig. 1B and C).
Gentamicin had similar effects at the same concentration in
R270X and R168X fibroblasts, but significantly lesser MeCP2
read-through of 15% and 18%, respectively (Fig. 1B and C). In
R294X fibroblasts, NB54 had dose-dependent effect in increasing
read-through efficiency between 15% and 24% at increasing drug
concentrations from 50 to 800 mg/ml (Fig. 1A). Gentamicin
showed different kinetics for the same mutation with maximal
read-through of 24% at 400 mg/ml and decreased efficiency at a
higher concentration (Fig. 1A). Basal levels of the full-length
MeCP2, in the range of 25–50% (relative to HFF), were detected
in all RTT fibroblasts (Fig. 1A–C), which result from XCI
variability in primary cultures reflecting the expression of the
active MeCP2 allele. In all RTT fibroblasts, NB54 effect was
apparent at concentrations as low as 50 mg/ml in increasing up to
15% MeCP2 read-through, in addition, NB54 was tolerated at
higher concentrations compared to gentamicin. However, both
aminoglycosides demonstrated a degree of cell toxicity (LC50)
even during short-term treatment (48 h) with gentamicin and
NB54 in HEK293 and HFF cells (Table 1).
Efficiency of NB54 in various RTT nonsense mutations
Mutations specific effects of NB54 were further reproduced
treating R294X, R270X and R168X fibroblasts with 400 mg/ml
NB54 for 5 days (Fig. 2A and B) that was previously found optimal
in R294X (Fig. 1A). This experiment independently demonstrated
that NB54 was more effective in R168X (UGA G), with increased
38% read-through compared to 18% and 27% in R294X (UGA
U) and R270X (UGA A), respectively. The difference between this
and previous findings (Fig. 1) of NB54 effect at the concentration
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PLoS ONE | www.plosone.org 2 June 2011 | Volume 6 | Issue 6 | e20733Figure 1. Aminoglycosides produce full-length MeCP2 in primary RTT fibroblasts. Western blot analyses of nuclear protein extracts from
gentamicin- and NB54-treated (50–800 mg/ml for 5days) and untreated RTT fibroblasts. 20 mg of nuclear protein extract were loaded into each lane;
full-length MeCP2 was detected using anti-MeCP2 C-terminal antibody. Graphs indicated mean 6 SEM of read-through efficiencies that were
determined using full length MeCP2 densitometric readings at each point normalized to emerin for protein load correction, subtracting the no-drug
point in each experiment for correction of MeCP2 background expression and XCI variability and dividing by human foreskin fibroblasts (HFF)
reference for fully active wild type MeCP2 (n=3 independent experiments). Statistical significance by Student’s t test is indicated (*). (A) R294X
(t=5.8, p,0.05), (B) R270X (t=2.6, p,0.05), (C) R168X (t=2.7, p,0.05).
doi:10.1371/journal.pone.0020733.g001
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expression MECP2 RNA levels in R294X fibroblasts treated with
100 mg/ml NB54 for 5 days, we observed insignificant differences
in MECP2_e1 and _e2 expression before and after NB54
treatment (less than 25%, Student’s t test p.0.05) and could be
attributed to XCI variability (Fig. 3), thereby supporting the
notion that NB54 has no effect on the mRNA level.
Functionality of MeCP2 after NB54 treatment
Studying localization of the recovered full-length MeCP2 in
NB54-treated R294X fibroblasts by immunofluorescence with
MeCP2 C-terminal antibody (green), we found that MeCP2 was
targeted to the cell nucleus (DAPI blue) (Fig. 4), as expected. In
R294X fibroblasts treated with elevating concentrations of NB54
between 50 and 800 mg/ml, we also looked at the levels of MeCP2
and BDNF (Fig. 5A). We found dose-dependent recovery of the
full-length MeCP2 with increasing concentrations of NB54,
reproducing our previous findings with the same mutation
(Fig. 1A), a negligible satellite band could be due to non-specificity
of the MeCP2 antibody. More importantly, we found parallel
increase in BDNF levels with 2-fold maximum at 100 mg/ml
NB54, which decreased at higher drug concentrations (Fig. 5B).
Discussion
Recent insights from RTT animal model suggest that neuronal
dysfunction resulting from MeCP2 deficiency can be reversed,
even in the adult mice, once MeCP2 is recovered [21,22]. These
extraordinary findings prompt further efforts in developing
pharmacological approaches targeted at enhancement of MeCP2
levels and function in the CNS. As MECP2 nonsense mutations
Table 1. Cytotoxicity of gentamicin and NB54 in HEK293 and
HFF cells.
Aminoglycoside
a Cell toxicity LC50 (mg/ml)
b
HEK293 HFF
gentamicin 1.7360.35 2.160.20
NB54 3.5660.39 4.5460.24
Aminoglycoside-induced cell toxicity was measured in human embryonic
kidney cells (HEK293) and in human foreskin fibroblasts (HFF) treated for 48 h.
aAminoglycosides are sulfate salts (MWgentamicin=653.21 and MWNB54=652.81)
and concentrations refer to the free amine form.
bCell toxicity was calculated as ratio between the number of living cells in the
presence of aminoglycoside versus non-treated cultures. The half-maximal
lethal concentration (LC50) values were obtained from fitting concentration–
response curves to the data obtained from at least three independent
experiments, using GraFit 5 software.
doi:10.1371/journal.pone.0020733.t001
Figure 2. Aminoglycoside NB54 enhances read-through in primary RTT fibroblasts. (A) Western blot analysis of NB54-treated (400 mg/ml
for 5days) and untreated RTT fibroblasts with R168X (CGA G.UGA G), R270X (CGA A.UGA A) and R294X (CGA T.UGA U) mutations, using MeCP2 C-
terminal antibody. 30 mg of nuclear protein extract were loaded into each lane. Read-through efficiency was determined using full length MeCP2
densitometric readings normalized to actin for protein load correction, subtracting the no-drug point in each experiment for correction of MeCP2
background expression and XCI variability, and dividing by human foreskin fibroblasts (HFF) reference for fully active wild type MeCP2 (n=3
independent experiments); (B) Effect of NB54 treatment was quantified by densitometric developed Western blot analysis (n=3 independent
experiments).
doi:10.1371/journal.pone.0020733.g002
Figure 3. MECP2 mRNA expression levels following treatment
with NB54. Total mRNA was purified from NB54-treated (100 mg/ml for
5days) and untreated R294X fibroblasts. Expression levels of both
MECP2_e1 and _e2 isoforms were determined by real-time qPCR using
GAPDH levels as an internal reference. Experiments were performed in
triplicates.
doi:10.1371/journal.pone.0020733.g003
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MeCP2 are relatively common in RTT, pharmacological
suppression of these mutations by small molecules, such as
aminoglycosides, could be potentially promising for human
patients. So far, the most substantial experience has been obtained
with gentamicin in restoring the expression of functional
dystrophin and cystic fibrosis transmembrane conductance
regulator (CFTR) proteins in mouse models [28,29] and in human
patients [36,37]. Especially encouraging recent reports indicated
that enhancement from 1% to only 5% of normal CFTR levels
may greatly reduce the severity or eliminate principal manifesta-
tions of cystic fibrosis [30,38]. However, severe ototoxicity and
nephrotoxicity of gentamicin [32,33] and its reduced read-through
efficiency at subtoxic doses, as well as its limited permeability
through the blood-brain-barrier [32], have limited its clinical use
[30], specifically for CNS disorders. Currently, only a limited
number of aminoglycosides, including gentamicin, amikacin, and
tobramycin, are in clinical use as antibiotics for internal
administration in humans, among these, tobramycin does not
have nonsense suppression activity.
The newly developed aminoglycoside NB54 has been demon-
strated as both, appreciably more effective in nonsense suppression
and less toxic than gentamicin [35], enabling read-through of
specific nonsense mutations underlying important human genetic
disorders, i.e. Usher syndrome, cystic fibrosis, Duchenne muscular
dystrophy and Hurler syndrome and being 8-fold less toxic than
Figure 4. NB54 treatment in RTT fibroblasts recovers full-length MeCP2 at the nucleus. Immunofluorescence studies of untreated (A–C)
and NB54-treated (D–F) R294X fibroblasts, using MeCP2 C-terminal antibody. Staining of the full-length MeCP2 (green signal in D, F) corresponds with
the DAPI staining (blue signal in E, F), thus indicating its nuclear localization.
doi:10.1371/journal.pone.0020733.g004
Figure 5. NB54 treatment increases BDNF levels in R294X fibroblasts. (A) Western blots of MeCP2, BDNF and emerin proteins after NB54
treatment (50–800 mg/ml for 5days) in R294X fibroblasts; (B) Graph indicates mean 6 SEM of BDNF expression levels normalized to emerin at
different NB54 concentrations derived from three independent experiments (n=3).
doi:10.1371/journal.pone.0020733.g005
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precedent and recent studies of gentamicin suppressing MECP2
nonsense mutations in vitro using transfected HeLa [31] and
HEK293 [39] cell lines, we studied NB54 and gentamicin effects ex
vivo in primary fibroblasts derived from classical RTT patients.
Apart from R255X, we included the three most common RTT
causative MECP2 nonsense mutations, R294X, R270X and
R168X, all resulting in UGA stop codon that was demonstrated
as the most effective gentamicin read-through target [40]. Most
recent study also tested NB aminoglycosides in mouse fibroblasts
harboring MECP2 R168X mutation [41].
For all the three RTT nonsense mutations studied here, NB54
had better suppression effect than gentamicin in enabling to
achieve higher expression levels and higher read-though efficiency
of the full-length MeCP2 at lesser concentrations. NB54 effect was
mutation specific with peak efficiencies at 100 mg/ml in R270X
and R168X, and simple dose-dependent relationship in R294X
fibroblasts. The most significant NB54 effect was observed in
R168X (38% read-through efficiency) compared to R270X (27%)
and R294X (18%). The best read-through for gentamicin was
obtained in R294X (24%) compared to R270X (15%) and R168X
(18%) fibroblasts, thus reproducing previous studies of gentamicin
effect for the same MECP2 mutations in transfected HeLa and
HEK293 lines [31,39]. Apart from R294X fibroblasts, both drugs
had lesser efficiencies at concentrations higher that 100 mg/ml,
suggesting that both are toxic, but gentamicin was more toxic than
NB54 at the same concentrations, also evident from our cell
toxicity data (Table 1). Serum gentamicin concentrations above
12 mg/ml have been previously shown as toxic for clinical use. In
order to facilitate higher read-through effect, we experimented
with MeCP2 recovery using drug concentrations up to 800 mg/ml
and longer exposure time (5 days). It is of note that the emerin
expression levels do not reflect cytotoxicity to the same extent as
the cell counts, NB54 effect on emerin expression was minimal
(Figure 1A–C), emerin being frequently used in Western blot
analyses as internal control for nuclear protein variation [42].
The issue of the significance of nucleotide context, particularly
the position +4 immediately following the stop codon, in dictating
the read-through efficiency has not been entirely resolved. Several
studies suggested that the gentamicin permissive read-through is
affected by the hierarchy C.U.G$A at this position [36,40],
while other studies did not support their findings [43,44]. The
present study supports the notion that the nature of nucleotide +4
may have contributing effect on NB54-induced read-through of
MECP2 nonsense mutations, as R168X (UGA G) had higher read-
through than R270X (UGA A) and than R294X (UGA U) (Fig. 2).
Effects of other factors, especially those involved in mRNA
stabilization and escape from nonsense mediated mRNA decay
(NMD) [44,45] cannot be ruled out and should be investigated in
future studies. Additionally, as aminoglycosides mechanism of
action involves binding to the 16S rRNA and interfering with the
ribosomal proofreading [27,46], we suggest that NB54 does not
affect the expression of normal MeCP2 allele (25–50% back-
ground levels) and that the observed increase in MeCP2 levels is
predominantly resulting from suppression of the MeCP2 nonsense
allele. Due to the same reason, NB54 treatment did not
significantly affect the expression levels of both MECP2_e1 and
_e2 transcripts. We have previously reported that MECP2
truncating mutations (nonsense or frame-shift deletions) are
associated with lower MECP2 RNA levels in peripheral blood
possibly due to the nonsense mediated mRNA decay mechanism
[47], suggesting that the truncated MeCP2 protein should be also
reduced in RTT fibroblasts.
One of the limitations of this study is variability of the
background MeCP2 expression (no drug), which makes the
interpretation and comparisons between various drug effects
difficult (Fig. 1A–C). This phenomenon has been known from
other studies of premature termination codons (PTC) in CFTR
and dystrophin genes [44,48]. In our experiments, this problem is
accentuated by XCI variability in primary fibroblasts from RTT
heterozygous females, thereby necessitating standardization of the
read-through efficiency considering background MeCP2 expres-
sion (no drug), fully active MeCP2 reference (HFF) and emerin.
Future studies may resolve this drawback using single-cell
subcloning of primary RTT fibroblasts, thus enabling to compare
between expression levels of the active and non-active MeCP2
alleles, as well as the normal and truncated MeCP2. This
approach has already been used for other MECP2 mutations in
female RTT fibroblasts [49]. Hemizygous RTT male fibroblasts
harboring MECP2 nonsense mutation could also be helpful in
resolving this question, but such patients are extremely rare and
are often misdiagnosed.
Our maybe most interesting finding has been to show that
NB54 treatment at 100 mg/ml induces up to 2-fold increase in the
BDNF levels, which was reduced at higher NB54 concentrations
(400–800 mg/ml) probably due to toxic effects. BDNF is the one of
the most important MeCP2 targets, being crucially involved both,
in synaptic plasticity during brain development [50] and in adults
[51]. Mechanism of MeCP2 action on BDNF expression is not
entirely clear, since it was shown that active MeCP2 represses
BDNF in vitro [14,15], however brain Bdnf was decreased in vivo in
Mecp2-null mice [52,53], and was up-regulated in MeCP2-
overexpressing mice [16]. In addition, BDNF and other MeCP2-
dependent factors were up-regulated after partial rescue of MeCP2
deficiency in vitro using HDAC inhibitors [42]. Regardless of their
relationship, BDNF enhancement in Mecp2-deficient mice was
shown to significantly improve the RTT-like phenotype and even
to enable its partial rescue [52]. Although the role BDNF in
fibroblasts is not clear, our findings of concomitant increase in the
full-length MeCP2 and BDNF levels resulting from NB54
treatment of RTT fibroblasts suggest that the recovered MeCP2
may have retained its functional properties, which is moreover
supported by its appropriate nuclear translocation.
In summary, this study proposes NB54 as a potential new
therapeutic agent for RTT nonsense mutations, and in so doing
supports the ‘‘proof of principle’’ that some RTT causative
MECP2 nonsense mutations can be at least partially suppressed by
less toxic aminoglycosides and aminoglycoside mimetics. This
therapeutic approach is particularly attractive for RTT, as
aminoglycosides are probably acting only on the mutated allele
and thus enabling to avoid MeCP2 over-expression. In addition,
aminoglycosides mechanism of action is not dependent on
knowing the exact MeCP2 function and underlying biology.
Another potentially interesting agent with a capability to suppress
premature protein termination without obvious side effects, is
PTC124 [54], although its effects on CNS disorders including
RTT are yet to be explored. In the same way, further studies of
NB54 effects should be carried out in mouse model with one of the
MECP2 nonsense mutations looking at NB54 permeability
through the blood-brain barrier, distribution in brain tissue and
recovery of RTT symptoms.
Methods
Patient selection
RTT patients were recruited from the Israeli Rett Center
operating at the Safra Pediatric Hospital at the Sheba Medical
Suppression of MECP2 Nonsense Mutations with NB54
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as ongoing clinical follow up. Study rationale was explained to the
patients’ legal guardians, after which they signed informed consent
for skin biopsy extraction approved by the Helsinki Committee at
Sheba Medical Center and by the Israeli Ministry of Health.
Primary fibroblasts culture and treatment
Fibroblasts were expanded from patients’ skin biopsies and
cultured in Dulbecco’s modified Eagle’s medium (Biological
Industries, Israel) supplemented with 10% fetal calf serum (FCS),
2 mM L-glutamine, 100 mg/ml streptomycin and 100 units/ml
penicillin (Biological Industries) at 37uC in humidified incubator
with 5% CO2. Human foreskin fibroblasts (HFF) used as reference
for normal MeCP2 expression were cultured in the same
conditions. Gentamicin sulfate (Biological Industries) or NB54
sulfate were added into the medium in concentrations ranging
from 50 to 800 mg/ml and cells were grown for 3 to 5 days.
RNA extraction and real-time quantitative PCR
Total RNA was extracted using Trizol reagent (Invitrogen,
USA) according to manufacturer’s protocol. First-strand cDNA
was generated from 1 mg total RNA in the presence of random
hexamer primers using High Capacity cDNA reverse transcription
kit (Applied Biosystems, USA). Gene expression was quantified by
real-time PCR using SYBR green PCR mix (Kapa Biosystems,
USA) in the presence of specific primers for MECP2_e1 and _e2
isoforms [10] compared to the GAPDH gene. Signals were
analyzed on ABI Prism 7900 SDS (Applied Biosystems). All the
reactions were performed in triplicates and means were compared
using Student’s t-tests.
Nuclear protein extraction
Cells were harvested in ice-cold PBS, washed twice and
centrifuged. Nuclear proteins were extracted from cell pellets
using NucBuster protein extraction kit (Merk, Germany) and re-
suspended according to manufacturer’s protocol. Protein concen-
tration was determined by Bradford modified method (BCA
Protein Assay; Pierce, USA) and equal amounts of proteins were
subjected to Western Blot analysis.
Western blot analysis
Proteins were separated on 12% SDS-PAGE, transferred to
nitrocellulose membrane (iBlot, Invitrogen) and detected using
ECL SuperSignal West Pico Chemiluminescent Substrate
(Thermo Scientific, USA) and CL-XPosure X-ray films (Thermo
Scientific). Primary antibodies included: rabbit mouse monoclonal
C-terminal anti-MeCP2 (Mec-168, Abcam, UK), rabbit polyclonal
anti-BDNF (Alomone Labs Ltd, Israel), rabbit polyclonal anti-
emerin (Santa Cruz Biotec, USA) and goat polyclonal anti-actin
(Santa Cruz Biotec). Secondary antibodies were: peroxidase-
conjugated goat anti-rabbit, goat anti-mouse and donkey anti-goat
(Jackson ImmunoResearch Laboratories, USA) diluted 1:10,000.
Read-through efficiency was calculated by comparing expression
of the full-length C-terminal containing MeCP2 in RTT and HFF
fibroblasts, using digital densitometry by EzQuant software
(EzQuant Ltd, Israel). MeCP2 read-through efficiency data was
obtained from three independent experiments for each mutation
and at least two Western blots for each experiment; means6SEM
were compared using Student’s t-tests and statistically significant
differences (p,0.05) were indicated (*).
Immunofluorescence analysis
Cells were grown on coverslips and fixed with 4% paraformal-
dehyde in PBS for 20 min. Permeabilization included incubation
with 0.1% Triton X-100 for 5 min, washing with TBS (100 mM
Tris-HCl pH 7.5, 150 mM NaCl) and blocking with 5% skimmed
milk in TBS containing 0.1% Tween 20 (TBS-T) for 30 min, all at
room temperature. Incubations with primary antibody (C-terminal
anti-MeCP2, Abcam; 1:1000 dilution) and secondary antibody
(conjugated goat anti-mouse Alexa Fluor 488, Invitrogen; 1:500
dilution) were performed in blocking solution for 1 h each,
washing with TBS-T between and after incubations. Cells were
incubated before mounting with 49,6-diamineo-2-phenylindole
(DAPI) with antifade 1:10,000 dilution (Sigma-Aldrich, USA).
Cells were photographed using Improvision optic grid (Improvi-
sion, UK) acquisition and fluorescent microscope (Olympus,
USA).
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